rawfin.tv
Moleculin Biotech Reports Positive Interim Data from AML Trial
MarketsstocksAI Generated

Moleculin Biotech Reports Positive Interim Data from AML Trial

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Moleculin Biotech, Inc. announced positive interim blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for AML. The trial showed a 37% blinded CRc rate in venetoclax-failed patients.

moleculin-biotechclinical-trialsbiotechaml-treatmentpharmaceuticals

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks